Ukraine Agrees to Protect Kazakhstan Oil Exports via Black Sea 
Germany Warns of Daily Hybrid Warfare Threats 
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise 
US Expects Iran-Oman Hormuz Shipping Deal Soon 
Bezalel Smotrich Faces Election Battle as Israel’s Far-Right Vote Fractures 
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger 
US ‘Digging In’ Across Indo-Pacific, Pentagon Official Says 
New Zealand MMP Electoral System Faces Fresh Referendum Debate 
Trump Demands Iran Pay Compensation Over Deaths and Injuries 
Colombia President Abelardo De La Espriella Pledges Drug Crackdown, Economic Reforms 
Iran-Oman Hormuz Shipping Deal Nears Final Stage 
Myanmar Rejects ASEAN Special Envoy, Challenges Regional Peace Plan 
CDC Expands Ebola Screening Efforts at U.S. Entry Points Amid Congo and Uganda Outbreak 
Taiwan Tests Penghu Defense, Mobile Internet Limits in War Drills 
SEC Moves to Dismiss Insider Trading Case Against Trump-Pardoned Terren Peizer 
A panel of independent U.S. vaccine experts has announced plans to review the long-standing recommendation for administering the hepatitis B vaccine at birth. The Vaccine Integrity Project, an organization focused on ensuring vaccine safety and efficacy, said it expects to complete its review by early December. The move follows a decision by a federal advisory committee under the Centers for Disease Control and Prevention (CDC) to delay a vote on whether to postpone the first hepatitis B dose for newborns of mothers who test negative for the virus.
The review will analyze decades of scientific research on the safety, effectiveness, and public health outcomes of administering the hepatitis B vaccine within the first 24 hours of life. It will also evaluate the potential risks of delaying the vaccine, including missed opportunities for immunization due to incomplete maternal screening or lack of follow-up.
Currently, the CDC and World Health Organization recommend that all newborns receive the hepatitis B vaccine shortly after birth to prevent mother-to-child transmission. Data show that infants infected at birth or within their first year face up to a 90% chance of developing chronic hepatitis B, which can lead to cirrhosis or liver cancer later in life.
The discussion has gained political attention after President Donald Trump questioned the necessity of giving the vaccine at birth, suggesting instead that it could be delayed until age 12, citing its transmission through sexual contact. However, health experts emphasize that perinatal infection remains a significant transmission route.
Since the introduction of widespread vaccination, hepatitis B infection rates in the United States have dropped by nearly 90%, from about 9.6 per 100,000 people before the vaccine program began to around one per 100,000 in 2018. Currently, six hepatitis vaccines are approved for use in the U.S., continuing to play a vital role in reducing the disease’s prevalence and protecting future generations.
